St. Louis American

2024ASCO｜Memorial Sloan Kettering Cancer Center (MSK)’s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations

TF overexpression is associated with thrombosis, metastasis and poor prognosis in solid tumors, including cervical and pancreatic cancer. MRG004A is a novel anti-TF monoclonal antibody conjugated (ADC ...
FiercePharma

Lonza Group AG : Lonza enters development and manufacturing agreement with Genmab A/S

Lonza enters development and manufacturing agreement with Genmab A/S for a novel antibody drug conjugate (ADC), HuMax-TF TM • This agreement secures a development and cGMP manufacturing plan for ...
Seeking Alpha

Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal

Multitude Therapeutics out-licensed global rights (ex-Greater China) for its Tissue Factor ADC to Denmark’s Adcendo in a $1 billion agreement. Huadong Pharmaceutical acquired rights for two immune ...
Nasdaq

Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors

- ICON-2 is pharmacologically more potent in vivo and in vitro, with better nonclinical tolerability, compared with a monomethyl auristatin E (MMAE) anti-TF antibody-drug conjugate (ADC) - - Data ...

Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors

More information can be found at: https://clinicaltrials.gov/study/NCT07227168 .
GEN

Lonza to Manufacture Genmab’s Tissue Factor-Targeting Antibody-Drug Conjugate

CMO will produce fully human HuMax-TF antibody and also construct final ADC candidate. Lonza is to provide Genmab with development and cGMP manufacturing expertise for the latter’s preclinical-stage ...
Business Wire

Seattle Genetics Highlights Promising Data with Tisotumab Vedotin in Cervical Cancer at ESMO 2017 Congress

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that preliminary clinical data for tisotumab vedotin from a Genmab-sponsored phase 1/2 clinical trial (GEN701) ...
GEN

Genmab Taps into Seattle’s ADC Technology to Develop Anticancer HuMax-TF Conjugate

Firm may opt to co-develop products after Phase I trials. Seattle Genetics and Genmab shook hands on an antibody-drug conjugate (ADC) research collaboration that gives the latter rights to use Seattle ...
FiercePharma

Ventana signs companion diagnostic agreement with international biotech for antibody drug conjugate program

TUCSON, Ariz., April 3, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into an agreement with Genmab A/S, Copenhagen, ...
MarketWatch

2024ASCO Memorial Sloan Kettering Cancer Center (MSK)'s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations

CHICAGO, June 12, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 31 to June 4, shone a spotlight on MRG004A, a novel antibody-drug ...
KTLA

2024ASCO｜Memorial Sloan Kettering Cancer Center (MSK)'s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations

TF overexpression is associated with thrombosis, metastasis and poor prognosis in solid tumors, including cervical and pancreatic cancer. MRG004A is a novel anti-TF monoclonal antibody conjugated (ADC ...